Q2 2025 Jaguar Health Inc Earnings Call Transcript
Key Points
- Jaguar Health Inc (JAGX) reported a 35% increase in revenue for Q2 2025 compared to Q1 2025, and a 10% increase compared to Q2 2024.
- The company achieved significant clinical milestones with Crofelemer, showing promising results in reducing TPN requirements for patients with intestinal failure.
- Crofelemer has orphan drug designation in the US and Europe, offering opportunities for expedited development and regulatory approval.
- The company is pursuing business development partnerships to generate non-dilutive funding, which could enhance financial stability.
- Jaguar Health Inc (JAGX) is actively expanding its product pipeline, including trials for cancer therapy-related diarrhea and animal health products.
- The company reported an increase in net loss attributable to common shareholders, rising from $9.5 million in Q2 2024 to $10.4 million in Q2 2025.
- Loss from operations increased by $800,000 from the previous year, indicating ongoing financial challenges.
- The OnTarget trial did not meet its primary endpoint for all tumor types, limiting the immediate impact of the study.
- Despite revenue growth, the company continues to face significant operational losses, highlighting the need for effective cost management.
- The market for some of Jaguar Health Inc (JAGX)'s products, such as those targeting ultra-rare diseases, is limited, potentially impacting long-term revenue potential.
Good morning. Before I turn the call over to management, I'd like to remind you that management may make forward-looking statements relating to such matters as continued growth prospects for the company, uncertainties regarding market acceptance of products, the impact of competitive products and pricing, industry trends and product initiatives, including products in development stage, which may not achieve scientific objectives or meet stringent regulatory requirements.
Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These statements are made based on current available information and the management's current assumptions, expectations, and projections about future events. While management believes its assumptions, expectations, and projections are reasonable in view of the currently available information, you are cautioned not to place undue reliance on forward-looking statements.
The company's actual results may differ materially from those discussed during
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
